Eltrombopag/Eltrombopag (Eltrombopag) Chinese instructions

1. Indications:Eltrombopag/Eltrombopag is a drug used to treat specific types of thrombocytopenic diseases. The degree of transfusion dependence required in patients with disease including immune thrombocytopenic purpura (ITP) and refractory myelodysplastic syndrome (MDS).

2. Mechanism of actionAnd pharmacology: Eltrombopag/Eltrombopag is a thrombopoietin receptor agonist (TPO-RAs), by binding to TPO-R (thrombopoietin receptor), stimulate stem cells in the bone marrow to produce more platelet precursor cells, thereby increasing the production and release of platelets.

Eltrombopag/Eltrombopag promotes the proliferation and differentiation of stem cells in the bone marrow and promotes the production of platelets by combining with TPO-R. It can increase platelet counts and reduce the need for blood transfusions in ITP patients. In MDS patients, it can also increase platelet counts and reduce transfusion dependence.

3. Dosage and usage:

Idiopathic thrombocytopenic purpura (ITP): Adults and children: The starting dose is generally 50mg orally per day, the dose is adjusted based on platelet count, and the maximum dose does not exceed 75mg per day.

Chronic liver disease-related thrombocytopenia: Adults: The starting dose is generally 25mg orally per day. The dose is adjusted based on platelet count. The maximum dose does not exceed 75mg per day.

4. Side effects:Eltrombopag/Eltrombopag may cause the following side effects: headache, nausea, diarrhea, vomiting, epistaxis, fatigue, skin itching, rash,Myalgia, joint pain, High blood pressure, Drowsiness, etc.

5. Warnings and precautions:

1.Bleeding risk: Patients should have regular platelet count checks, pay attention to bleeding symptoms, and report to the doctor in a timely manner.

2.Liver function monitoring: Liver function should be checked regularly during treatment, especially in patients with chronic liver disease.

3.Tumor risk: There are reports that Eltrombopag/Eltrombopag is associated with an increased risk of liver malignant tumors and requires close monitoring.

4.Pediatric use: For use in pediatric patients, the dose should be adjusted according to the doctor's recommendations.

6. Contraindications:

1.It is contraindicated for those who are allergic to eltrombopag/eltrombopag or any ingredients in the drug.

2.Use with caution in pregnant and lactating women.

7. Drug interactions:

1.When combined with anticoagulant drugs (such as warfarin), the risk of bleeding may increase and should be used with caution.

2.When combined with antacid drugs (such as omeprazole), it may affecteltrombopag/eltrombopag absorption should be avoided at the same time.

8. Medication for special groups:

1.Elderly patients: Generally, they can be used at standard doses, but side effects should be closely monitored.

2.Children: For pediatric patients, the dose should be adjusted based on weight and condition, and follow physician recommendations.

3.Patients with hepatic impairment: Patients with severe hepatic impairment should use it with caution and dose adjustment may be required.

9. Availability and price situation: Eltrombopag/Eltrombopag has been launched in China and is included in medical insurance. Because medical insurance policies vary from place to place, the price after reimbursement is also different. For details, please consult the local hospital pharmacy or medical insurance bureau. Eltrombopag abroad is available in both original and generic versions. The original version of Eltrombopag includes the Turkish original version and the Indian version of the original version. The prices of the two are almost the same, about more than a thousand yuan. There are many versions of generic drugs, including generic drugs from India, Bangladesh, and Laos. The cheaper generic drug is Eltrombopag from Everest Pharmaceuticals in Bangladesh, which costs about a few hundred yuan; other generic drugs are about one to two thousand yuan, and the ingredients of the original drug and the generic drug are basically the same.

In short,Eltrombopag/Eltrombopag is a drug used to treat idiopathic thrombocytopenic purpura and chronic liver disease-related thrombocytopenia. It stimulates stem cells and precursor cells in the bone marrow to promote the production and release of platelets, thereby increasing the number of platelets and improving coagulation function. When using it, patients should closely follow the doctor's advice and undergo relevant examinations regularly to ensure safe and effective treatment. If you have any adverse reactions or questions, you should consult your doctor promptly.